anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Preterm neonates are at risk for neurodevelopmental impairment, especially those with intraventricular hemorrhage (IVH). Cerebral vasospasm (VSP) is a common complication after subarachnoid hemorrhage (SAH) in adult population, but it is unknown if preterm neonates with IVH may develop it. We prospectively enrolled premature newborns < 32 weeks with IVH and without IVH. All patients received serial transcranial sonography through the temporal window of the middle cerebral artery, anterior cerebral artery, posterior cerebral artery, and the internal carotid artery with transcranial Doppler sonography days 2, 4, and 10 of life. Cerebral blood velocities (CBFVs) were measured including median velocity flow (MV), peak systolic velocity (PSV), and maximum end-diastolic velocity (EDV). Resistance index and pulsatility index were calculated. VSP was defined as an increase of 50% in the baseline velocity per day and/or a Lindegaard ratio higher than 3. Fifty subjects were enrolled. None of the patients with IVH showed elevation of MV or a Lindegaard ratio > 3. There were no differences between IVH and without IVH groups regarding resistance index and pulsatility index.    Conclusion: Preterm infants with IVH do not present a pattern of VSP analyzed by Doppler transcranial ultrasound in this pilot study. What is Known: • In adult population with subarachnoid hemorrhage the most treatable cause of cerebral ischemia is due cerebral vasospasm but is unknown if premature newborn may have vasospasm due the extravasation of blood in the context of intraventricular hemorrhage What is New: •In this pilot study we did not find in premature newborn with intraventricular hemorrhage signs of vasoespam measured by transcranial color doppler ultrasound.
The Federal Aviation Administration is interested in investigating inexpensive yet effective methods to mitigate the adverse effects of aviation noise on sleep. The sleep of up to 28 subjects will be monitored with polysomnography and actigraphy over 7 consecutive nights in groups of 4 exposed to various sound conditions (aviation noise; broadband noise; aviation noise plus earplugs; aviation noise plus broadband noise at various decibel \[dB\] levels). Subjects will fill out surveys, perform cognitive tasks and a hearing test before and after each sleep period. The study will be performed in the Chronobiology Isolation Laboratory (CIL) in the Hospital of the University of Pennsylvania. This newly constructed facility includes 4 acoustically isolated bedrooms and a high-fidelity sound system. Eligible subjects are age 21-50, free of psychiatric conditions that preclude participation, and maintain a self-reported regular sleep schedule of 6-8.5 hours per night as verified by six days of ambulatory actigraphy and daily logs.
The present invention relates to a computer implemented method for controlling a gas detector, a gas detector, a control system for detecting an incontinence event, and a computer implemented method for detecting an incontinence event. The method for controlling a gas detector comprises receiving a plurality of datasets from the gas detector. Each dataset is associated with a time interval and comprises at least one environmental measurement; and at least one detected level of ammonia. The method comprises receiving one or more user measurements, where a user measurement comprises an incontinence state determined at a particular time. The method comprises determining criteria to identify an incontinence event, using the received plurality of datasets and the received user measurement; and transmitting the criteria to the gas detector. The criteria define a characteristic of a subset of data of the plurality of datasets indicating an incontinence event.
A method of preparing an extract from Senna leaves (Cassia Angustifolia) comprises reduction of the particle size of the Senna leaves, extraction with subcritical water and then removing the water to produce a pharmaceutically acceptable extract. The extraction may be conducted at 150-230Â°C and/or 15-100 bar. The water may be removed by evaporation, freeze drying or spray drying. The extract may be formulated in a self emulsifying drug delivery system (e.g. using lauroyl macrogolglycerides and a surfactant) to improve the oral bioavailability of the active constituents; it may be formulated in a topical vehicle (e.g. using cetostearyl alcohol, macrogol cetostearyl ether, liquid paraffin, parabens, water and propylene glycol). The extract may be similar to the corresponding methanolic extract. Extraction of Valerian, Rosemary, German Chamomile and Ginger root is also disclosed.
Aerobic interval will consist of a supervised aerobic interval training sessions 3 times/week. Duration will range between 45-50 min/session depending on the exercise energy expenditure (target expenditure \~450-500kcal/session). Each interval will have a total duration of 5 min, and it will be divided into 2 periods. The first period will consist of 3 minutes of high-intensity activity at 70-85% of predicted HRmax, and for the second period the intensity will be reduced to 60-65% of predicted HRmax for 2 minutes. The training sessions will be carried out outdoors at the trails located on campus. The activity will consist of walking and/or light jogging. The speed/incline will be changed depending on the participants' heart rate and perception using the Borg's rating of perceived exertion (RPE) as needed. The RPE for the first period range will be 13-17 (15-17 at the end of the period) and 10-12 for the second period.
1,243,454. Shaped pharmaceutical products. W. E. GAUNT. 18 March, 1969, No. 14138/ 69. Heading A5B. A method for producing biologically active dosage units includes casting on to a flat surface a solution containing at least one biologically active ingredient, and at least one film former (as defined) and evaporating off a major portion of the solvent at such a rate that no bubbles or other discontinuities form in the film produced, dividing the film into units of predetermined size, and further hardening the units by evaporating off the remaining solvent. A plasticizer such as dimethylphthalate, diethylphthalate, acetyltributyl citrate and acetyltriethyl citrate, may also be present. The compositions may, for example, be in the form of cubic, cuboidal or parallelopipedoid units. A number of suitable active ingredients are specified.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: solid pharmaceutical composition contains rasagiline or a pharmaceutically acceptable salt of rasagiline and particles of afibrillar microstructure of at least two sugar alcohols. The solid pharmaceutical composition containing rasagiline or its pharmaceutically acceptable salt can contain mixed aerating agent improving fluidity, and the particles of afibrillar microstructure of at least two sugar alcohols, additional sugar alcohol, additional fluidity improving agent and additional aerating agent. This invention presents the method of treating an individual suffering from Parkinson's disease. ^ EFFECT: rasagiline tablets under the invention are characterised by low fragility, sufficient hardness and quickly degrade in mouth cavity, eg for 50-90 seconds. ^ 58 cl, 2 tbl, 7 ex
PURPOSE:To provide a non-steroidal anti-inflammatory agent composition composed of a composition of piroxicam and natural albumin, having excellent absorbability and causing decreased gastrointesinal damage. CONSTITUTION:The objective composition can be produced either by contacting piroxicam with a natural albumin (preferably egg albumin or, in the case of using in a field having antigenicity problem, preferably human-originated albumin) in the presence of an aqueous solvent under high-speed agitation or by dissolving piroxicam kin a fatty oil and/or a fatty acid, adding the solution to a suspension of a natural albumin, stirring the mixture at a high speed and distilling out the aqueous solvent. The amount of piroxicam is preferably 5-100 pts. per 100 pts. of natural albumin. The concentration of the natural albumin suspension is >=1W/V%, preferably 5-25W/V%.
INTRODUCTION: Hypoxemia is a common complication of sedation. This meta-analysis aimed to evaluate the efficacy and safety of supraglottic jet oxygenation and ventilation (SJOV) in preventing hypoxemia during sedative procedures.
METHODS: Randomized controlled trials (RCTs) that compared SJOV with conventional oxygen therapy in sedated patients were searched in five databases (MEDLINE, EMBASE, Cochrane Library, China National Knowledge Infrastructure [CNKI], and Google Scholar) from their inception to March 2024. The primary outcome was the proportion of patients who developed hypoxia (SpO2 < 90%). The secondary outcomes included subclinical respiratory depression (90% ≤ SpO2 < 95%), severe hypoxemia (SpO2 < 75%), airway interventions, adverse events, hemodynamics, propofol dosage, and procedure time. The certainty of evidence was determined using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
RESULTS: Twelve trials (n = 3058) were included in the analysis. The evidence suggests that SJOV results in a large reduction in the risk of hypoxemia (risk ratio [RR], 0.26; 95% confidence interval, 0.19-0.36; low certainty) and subclinical respiratory depression (RR, 0.40; low certainty) compared with the control. SJOV likely resulted in a large reduction in the risk of severe hypoxemia (RR, 0.22; moderate certainty). In addition, it may result in a large reduction in the need for jaw lift (RR, 0.22; low certainty) and mask ventilation (RR, 0.13; low certainty). The risk of sore throat probably increases with SJOV (RR, 1.71; moderate certainty), whereas SJOV may result in little to no difference in nasal bleeding (RR, 1.75; low certainty). Evidence is very uncertain regarding the effect of SJOV on hemodynamics (very low certainty) and procedure time (very low certainty). SJOV probably resulted in little to no difference in sedative doses between the groups (moderate certainty).
CONCLUSION: According to the GRADE approach, SJOV likely results in a large reduction in the risk of severe hypoxemia but probably increases the risk of sore throat. Compared with the control, evidence suggests that SJOV results in a large reduction in the risk of hypoxemia, subclinical respiratory depression, and the need for airway manipulation, with little to no difference in nasal bleeding. The integration of SJOV into clinical practice may help minimize hypoxemic events in at-risk patients.
PURPOSE:To prepare a water-in-oil-type emulsion with excellent stability and feeling of use even in a low viscosity region. CONSTITUTION:In preparing a water-in-oil-type emulsion, a surfactant compsn. wherein a nonionic surfactant (A) consisting of a partial ester of a polyhydric alcohol with at least three hydroxyl groups with a fatty acid and being liq. at ordinary temp. and a water soln. (B) contg. 1-40wt.% amino acid or its salt and 1-20wt.% non-reductive sugar alcohol with at least five hydroxyl groups in a molecule are mixed so as to make the wt. ratio of the nonionic surfactant in the component (A) to the component (B) water soln. to be 1:1 to 1:20, is used. In addition, emulsifying is performed by incorporating at first an emulsifying agent consisting of an ethylene oxide 20-60 adduct to a hydroxyfatty acid triglyceride and furthermore, mixing an emulsifying agent compsn. therein, and then, adding water therein.
<P>PROBLEM TO BE SOLVED: To obtain a medicinal composition effective for treating mood disorders.  <P>SOLUTION: This medicinal composition contains a carbostyril derivative and a serotonin reuptake inhibitor. The carbostyril derivative contains aripiprasol and its metabolic products. The serotonin reuptake inhibitor contains fluoxetine, duloxetine, venlafaxine, milnacipran, citaloplam, fluvoxamine, paroxetine, sertraline and escitalopram. The mood disorders such as depression are effectively treated by using the carbostyril derivative together with the serotonine re-uptake inhibitor.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
The study team's understanding of diagnosis, treatment and outcomes of coronavirus disease 2019 (COVID-19) is rapidly evolving. First reports from China clearly indicate that older patients with underlying cardiovascular disease and/or cardiac risk factors demonstrate higher mortality rates. Most recent reports provided novel insights into the incidence of myocardial injury in COVID-19 patients and its association with adverse outcomes. In both studies, patients with myocardial injury manifested by elevated high-sensitivity troponin I (TnI) levels had significantly higher in-hospital mortality rates compared with those without myocardial injury, (59.6 and 8.9% (3) and 51 vs 4.5 %). Among patients with myocardial injury, higher levels of TnI were associated with higher mortality rates. While the highest mortality rates were observed in patients with elevated TnI and underlying cardiovascular disease (CVD), mortality rates were also considerable in patients with elevated TnI and without prior CVD. In contrast, patients with known cardiovascular disease without TnI elevation had more favorable outcomes. Cardiac injury was independently associated with an increased risk of mortality in patients with COVID-19. The arming reports clearly indicate that the data from larger populations from multiple centers are needed to further characterize and better understand the association between myocardial injury and adverse outcomes in COVID-19 patients.

II. STUDY AIM The aim of the proposed study is to analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system. In addition, the study team will explore the association between TnI levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for COVID-19 induced myocardial injury.

III. STUDY POPULATION By October 2020, there have been 4,695 COVID-19 positive patients treated in the Mount Sinai Hospital (MSH) and more than 1,1000 patients with COVID-19 had been healed and discharged. All consecutive patients admitted to the MSH system from February 2020 to October 2020 with laboratory-confirmed COVID-19 will be included in the retrospective study.
BACKGROUND: Paraplegia after spinal cord ischemia is a devastating condition in the clinic. Here, we develop an awake rabbit model of spinal cord ischemia with delayed paraplegia and explore the influence of ambient temperature on the outcomes after injury.
METHODS: A total of 47 male rabbits were involved in the present study. Transient spinal cord ischemia was induced by occluding the infrarenal abdominal aorta of awake rabbits at different ambient temperatures. To find the optimal conditions for developing delayed paraplegia, hindlimb motor function after ischemia was evaluated between experiments.
RESULTS: The onset and magnitude of ischemic injury varied with the ambient temperature maintained during the peri-ischemia period. More serious spinal cord injury occurred when ischemia was induced at higher temperatures. At 18°C, 25-minute ischemia resulted in 74% of rabbits developing delayed paraplegia. At a temperature of 28°C or higher, most of the animals developed acute paraplegia immediately. While at 13°C, rabbits usually regained normal motor function without paraplegia.
CONCLUSION: This awake rabbit model is highly reproducible and will be helpful in future studies of delayed paraplegia after spinal cord ischemia. The ambient temperature must be considered while using this model during investigation of therapeutic interventions.
<P>PROBLEM TO BE SOLVED: To provide a code reading system capable of reading collectively an identification code of a storing rack and identification codes of a plurality of works, and managing each work correlatively with a storage place on the storing rack.  <P>SOLUTION: This system has a plurality of vessels, the storing rack for storing vertically the vessels, and a code reader for reading the identification code. The storing rack has a rack identification code on the side face. Each vessel has a vessel identification code on the bottom face. The code reader has a scanner reading face for placing the storing rack thereon, and a projection means for projecting the rack identification code onto the scanner reading face. The code reader reads the rack identification code and the vessel identification code collectively as image data through the scanner reading face.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
The invention relates to a substituted, non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, a method for the production thereof, and a vaccine containing said substituted, non-coding nucleic acid molecule. The part concerning the invention consists of covalently coupling substituents to said carrier module and the novel properties resulting therefrom, the substituents being coupled to any nucleotides of the stem or the loops, i.e. hairpin-shaped loops. The inventive nucleic acid molecules can also be a component of a vaccine that is used for modulating the immune response in humans or higher animals. Also disclosed is a vaccine comprising a combination of inventive nucleic acid molecules and substituent-coupled, dumbbell-shaped, linear covalently closed expression constructs. Said combination vaccine can also be used as an adjuvant in the therapeutic or prophylactic vaccination of humans or higher animals or for in vitro or in vivo immune stimulation in humans or higher animals.
The Telephone-Administered Coping Effectiveness Training (teleCET) intervention is the attention-equivalent comparator and also comprises 5 sessions lasting approximately 45-50 minutes each. The teleCET intervention is based on the Lazarus and Folkman Transactional Model of Stress and Coping (Lazarus \& Folkman, 1984) and uses cognitive-behavioral principles to: (a) appraise stressor severity, (b) develop problem- and emotion-focused coping skills, (c) determine the match between coping strategies and stressor controllability, and (d) optimize coping through use of social support resources.
BACKGROUND: The burden of sepsis worsens due to the continuation of emerging pathogens such as multidrug-resistant Pantoea species.
METHODS: A multicenter study was conducted between October 2019 and September 2020 at four hospitals located in central, southern, and northern parts of Ethiopia. A total of 1416 sepsis patients were recruited and blood cultures were performed. At each study site, positive cultures were characterized by their colony characteristics, gram stain, and conventional biochemical tests. All Pantoea species were identified using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI TOF) and subjected to whole genome sequencing (WGS) using Illumina HiSeq 2500. The phylogeny structure of Pantoea isolates was calculated using IQ-TREE v1.6.12 from single-nucleotide polymorphisms detected by Snippy v.4.6.0 and filtered by Gubbins v.2.3.4. Average nucleotide identity was estimated by using OrthoANI v.0.93.1 on Shovill v.1.1.0 assemblies. Antimicrobial resistance genes and plasmid replicons were detected using ARIBA v.2.14.6. Phylogenetic trees were visualized using iTOLv.6.5.2.
RESULTS: Multiple Pantoea species include: P. dispersa (n = 19), P. septica (n = 1), and a novel Pantoea spp. (n = 1), were identified among sepsis patients. All P. dispersa isolates and the novel Pantoea species were isolated at Dessie Referral Hospital and displayed phylogenetic clonality, including the ubiquity of an IncM1 plasmid and identical antimicrobial resistance (AMR) gene profiles, encoding blaCTX-M-15, blaTEM-1D, blaSCO-1, and aac(3)-lla. The novel Pantoea spp. isolate harboured blaCTX-M-9 and blaTEM-1D and carried an IncN3 plasmid replicon. The P. septica was isolated at Tikur Anbessa Specialized Hospital in Addis Ababa and carried no detectable acquired AMR genes.
CONCLUSION: The emerging Pantoea spp. carrying multiple AMR genes were identified from sepsis patients. Implementation of strong infection prevention strategies and building surveillance capacity with advanced bacteriology laboratories capable of identifying multidrug-resistant emerging pathogens is strongly recommended.
The aim of this study was to evaluate the growth performance, fermentation indices and meat quality of Sussex steers fed totally mixed rations that composed of graded inclusion levels of Napier grass (NP). Three experimental diets designated as diet 1 (0.0 g kg-1 NP: Control), diet 2 (300 g kg-1 NP grass) and diet 3 (600 g kg-1 NP) were formulated. Twenty-four male steers aged 8 months with an average body weight of 185.0 ± 30 kg were used. In a completely randomized design, the animals were allocated to the diets and fed for 120 days. Dietary NP inclusion reduced (P < 0.05) the animals' average daily gain and increased the feed efficiency. The steers' daily feed intake and final body weight decreased (P < 0.05) with a 600 g kg-1 inclusion level. The fermentation indices were not affected (P > 0.05) by the inclusion. While the inclusion reduced (P < 0.05) warm muscle temperature, it had no effect (P > 0.05) on carcass dressing percentage, warm and cold initial and ultimate pH. However, 600 g kg-1 inclusion level reduced (P > 0.05) warm and cold carcass weights. Meat physical attributes, moisture characteristics and tenderness were not affected (P > 0.05) by dietary treatments, except for the 7-days aged meat thaw loss, which increased at 600 g kg-1 inclusion level. Inclusion of 300 g kg-1 increased meat protein and fat, but dry and organic matter contents decreased with increasing inclusion levels. Dietary inclusion of NP grass up to 300 g kg-1 in steers' diets improved feed intake, carcass traits and yielded meat high in protein and fat.
The present invention relates to an arsenic and enzyme composite medicinal prepn. for directly applying on cancer focus and its prepn. technology, compared with the patentee's application No.92104358.9 on May 31, 1992 "Prepn. method of Arsenic prepn. for directly applying on cancer focus", the new formulation increases enzyme and procaine hydrochloride, the enzyme can quickly liquify withered and killed cancer cell so that promotes the arsenic prepn. diffuse to the whole cancer body in short time and makes the whole cancer body withered and killed and achieves the aim of quickly curing cancer. The procaine hydrochloride can reduce and eliminate the pain of patient.
Secondary injury of cerebral hemorrhage is induced by systemic inflammatory cascades, which are related to perihematomal brain edema, cellular apoptosis, and the disruption of the blood-brain barrier. This study was to specifically elaborate the relationship of circulating/cerebrospinal T lymphocytes and Glasgow Coma Scale (GCS) score at 6 months after intracerebral hemorrhage (ICH). The enrolled patients were divided into 2 groups based on GCS score: the favorable prognosis group (GCS > 12) and unfavorable prognosis group (GCS ≤ 12). T lymphocyte subpopulations were analyzed by flow cytometry. A total of 30 samples of peripheral blood and 17 samples of cerebrospinal fluid were collected and analyzed, including 19 cases and 12 cases in the favorable prognosis group (GCS > 12) respectively. Both CD3+ and CD3+CD4+ T lymphocyte counts on Day 1 after ICH were lower in the peripheral blood of patients with unfavorable prognosis (GCS ≤ 12) (P = .025 and .022, respectively). There were correlation trends between the GCS scores and CD3+ T lymphocyte count (P = .0144), and CD3+CD4+ T lymphocyte count (P = .0135). In cerebrospinal fluid, there was a close correlation between the GCS scores and CD3+CD4+ percentage, CD4+/CD8+ ratio, CD3+ and CD3+CD4+ T lymphocyte counts. The area under the curve of CD4+/CD8+ T lymphocyte ratio was the largest among them (P = .000 and area under the curve = 0.917), with a significantly high specificity and sensitivity (0.917 and 1.000). Based on cerebrospinal fluid samples, the CD4+/CD8+ T lymphocyte ratio on Day 1 after ICH may be a more significant indicator to predict the short-term prognosis at 6 months after ICH.